Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What is the Anticipated CAGR of the Sartans Market, and What Factors Will Drive It?

Over the last few years, the sartans market has witnessed consistent growth. It is set to expand from $21.36 billion in 2024 to $22.18 billion in 2025, with a compound annual growth rate (CAGR) of 3.8%. Factors such as a rise in sedentary lifestyles, increase in obesity incidents, heightened awareness of cardiovascular diseases, growing healthcare spending, and an increased demand for generic antihypertensive drugs have been instrumental in driving the growth during the historic period.

The market for sartans is predicted to experience a consistent growth surge in the coming years, escalating to a worth of $26.07 billion by 2029, with CAGR pegged at 4.1%. The swelling in the projected period could be due to an escalating concentration on combined therapies, intensifying investment in pharmaceutical research and development, burgeoning demand in budding markets, development of healthcare infrastructure, and an ascending prevalence of lifestyle-related conditions. Foremost trends predicted for this period include the progression in drug delivery technologies, sophisticated manufacturing processes for APIs, creation of fixed-dose combination drugs, improvements in personalized hypertension treatments, and the formulation of new sartan derivatives.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24393&type=smp

What Are the Major Market Drivers Behind the Rising Adoption of Sartans Market?

The escalation in the occurrence of hypertension is projected to stimulate the expansion of the sartans market in the future. Hypertension, defined by a constant state of elevated blood pressure, amplifies the chances of developing heart diseases, strokes, and other serious health issues. The increasing prevalence of hypertension can be attributed to diets high in sodium and processed foods, which promote fluid accumulation and augment the strain on the heart. Sartans address hypertension through inhibiting angiotensin II, a hormone responsible for constricting blood vessels, thereby facilitating the relaxation and broadening of the vessels, bringing down the blood pressure and reducing the burden on the heart. The American Heart Association, a nonprofit organization based in the US, reported in January 2024 that there was a rise in deaths primarily caused by high blood pressure from 124,508 deaths in 2021 to 131,454 deaths in 2022. Hence, the escalating occurrence of hypertension is the primary contributor to the growth of the sartans market.

Which Key Market Segments Comprise the Sartans Market and Drive Its Revenue Growth?

The sartans market covered in this report is segmented –

1) By Product Type: Valsartan, Telmisartan, Losartan, Irbesartan, Azilsartan, Olmesartan

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

3) By Application: Hypertension, Cardiovascular Diseases, Kidney Diseases, Other Applications

4) By End-User: Hospitals, Diagnostic Laboratories, Other End-Users

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=24393&type=smp

Which Areas Are Leading Regions in the Sartans Market Expansion Across the Globe?

North America was the largest region in the sartans market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sartans market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Which Technological Trends Are Reshaping the Sartans Industry Dynamics?

Leading firms in the sartans market are prioritizing the enhancement of treatment efficacy and patient compliance by creating state-of-the-art products, such as sartans in tablet form. These are oral sartan drugs that counteract angiotensin II’s impact, leading to blood vessel relaxation and blood pressure reduction. Notably, in July 2024, Zydus Lifesciences, a pharmaceutical company hailing from India, secured approval from the US Food and Drug Administration (FDA) for their 40 mg and 80 mg Valsartan Tablets USP. Branded as Diovan, these tablets are used to manage hypertension and heart failure as well as improve survival rates after a heart attack in adults. They are also applicable to pediatric patients who are a year old and above.

View the full report here:

https://www.thebusinessresearchcompany.com/report/sartans-global-market-report

How Is the Sartans Market Conceptually Defined?

Sartans also known as angiotensin II receptor blockers (ARBs) are medications commonly prescribed to manage high blood pressure (hypertension) and heart failure. They block the action of angiotensin II, a hormone that causes blood vessels to constrict, by promoting relaxation of the vessels, lowering blood pressure, and improving circulation. Sartans help reduce the risk of strokes, kidney damage, and heart attacks in individuals with specific cardiovascular conditions.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=24393

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model